Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | ABL2 | P42684 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADK | P55263 | 4/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30941058 | 1.00 | SRC (0.45) | SRCEGFRABL1ABL2MTOR | |
| SCHEMBL30940983 | 0.95 | SRC (0.48) | SRCEGFRABL1ABL2MTOR | |
| SCHEMBL30941051 | 0.91 | SRC (0.45) | SRCEGFRABL1ABL2MTOR | |
| SCHEMBL25047606 | 0.91 | SRC (0.45) | SRCEGFRABL1ABL2MTOR | |
| SCHEMBL30941028 | 0.90 | SRC (0.47) | SRCEGFRABL1ABL2MTOR | |
| SCHEMBL30940730 | 0.88 | GPR119 (0.34) | SRCEGFR | |
| SCHEMBL25048945 | 0.88 | GPR119 (0.34) | SRCEGFR | |
| SCHEMBL31617972 | 0.86 | SRC (0.39) | SRCEGFRABL1ABL2ADK | |
| SCHEMBL25047935 | 0.83 | SRC (0.37) | SRCEGFRABL1ABL2ADK | |
| SCHEMBL25048948 | 0.83 | GPR119 (0.35) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |